BENEFIT OF SACUBITRIL/VALSARTAN THERAPY IN CLINICALLY STABLE PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Clinical instability has been suggested as a potential criteria to determine which patients should be considered for ACE/ARB replacement therapy with LCZ696 (sacubitril/valsartan). We identified patients who were clinically stable, defined as NYHA Class II with no history of prior heart failure